HC Wainwright Has Negative Forecast for ALDX FY2027 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Investment analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will post earnings per share of $0.08 for the year, down from their previous estimate of $0.11. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share.

Separately, BTIG Research reaffirmed a “buy” rating and set a $9.00 price target on shares of Aldeyra Therapeutics in a report on Monday, November 10th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Aldeyra Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Aldeyra Therapeutics Stock Down 5.8%

Shares of ALDX traded down $0.30 during mid-day trading on Thursday, reaching $4.90. 458,937 shares of the stock traded hands, compared to its average volume of 806,765. The stock has a fifty day simple moving average of $5.03 and a 200 day simple moving average of $5.17. Aldeyra Therapeutics has a 12-month low of $1.14 and a 12-month high of $7.20. The firm has a market cap of $294.88 million, a price-to-earnings ratio of -8.60 and a beta of 0.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03.

Institutional Trading of Aldeyra Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company raised its stake in Aldeyra Therapeutics by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,074 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 1,972 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Aldeyra Therapeutics by 2.7% in the 2nd quarter. Rhumbline Advisers now owns 77,494 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 2,018 shares during the period. Brighton Jones LLC boosted its holdings in shares of Aldeyra Therapeutics by 11.4% in the third quarter. Brighton Jones LLC now owns 19,945 shares of the biotechnology company’s stock worth $104,000 after buying an additional 2,046 shares during the period. Charles Schwab Investment Management Inc. grew its position in Aldeyra Therapeutics by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 152,787 shares of the biotechnology company’s stock worth $791,000 after purchasing an additional 2,309 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec grew its holdings in shares of Aldeyra Therapeutics by 25.8% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 2,500 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.